Odylia Therapeutics Announces Partnership with PURA Syndrome Foundation
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....
Atlanta, GA, September 10, 2024 — Innovators in Rare Disease Diagnosis and Care Compete for The Amgen Prize and $150,0000 in Prize Funding at the Concordia Annual Summit Odylia announced as top 5 finalist for the Amgen Prize: Innovation for Patients with Rare Disease. Follow the link...
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....
Atlanta, GA, May 20, 2024 — Odylia Therapeutics, a nonprofit biotechnology company, received a Translation Research Award for $1.5 million from the Foundation Fighting Blindness to accelerate the development of a novel gene therapy (OT-004) to treat vision loss caused by mutations in the RPGRIP1...
Atlanta, GA, October 2, 2023 — Medibanx, a patient-centric platform that powers medical research through the aggregation and analysis of longitudinal real-world patient data, is excited to announce a partnership with Odylia Therapeutics, a nonprofit biotechnology company focused on the development of treatments for people...
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....